Prelude Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Prelude Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,600	Closed	-$83K	–	2017
2017 Q1	$83K	Sell	6,600 -69,360	-91%	-$838K	0.01%	848
2016 Q4	$1.01M	Buy	75,960 +3,704	+5%	+$63.3K	0.12%	206
2016 Q3	$1.71M	Buy	72,256 +69,173	+2,244%	+$1.86M	0.18%	130
2016 Q2	$89K	Buy	3,083 +2,083	+208%	+$67.9K	0.01%	807
2016 Q1	$32K	Sell	1,000 -1,400	-58%	-$49.2K	﹤0.01%	1045
2015 Q4	$103K	Buy	2,400 +1,600	+200%	+$63.9K	0.02%	800
2015 Q3	$28K	Sell	800 -500	-38%	-$22.5K	﹤0.01%	1194
2015 Q2	$60K	Buy	+1,300	New	+$61.7K	0.01%	1096
2014 Q3	–	Sell	-1,400	Closed	-$42K	–	2293
2014 Q2	$42K	Buy	+1,400	New	+$37.8K	0.01%	1444
2014 Q1	–	Sell	-3,684	Closed	-$93K	–	2235
2013 Q4	$93K	Buy	+3,684	New	+$82.2K	0.02%	865

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Prelude Capital Management's IPXL Position: Q2 2017 in Review

Prelude Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2017, closing a stake of 6,600 shares — an estimated $83K sold.

Prelude Capital Management first reported a position in IPXL in Q4 2013 and held it in 10 quarters. The position peaked at $1.71M in Q3 2016. 172 funds tracked by Wall St. Rank hold IPXL as of Q2 2017.

Prelude Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2017 after selling out during the quarter.
Prelude Capital Management sold 6,600 Impax Laboratories, Inc. shares in Q2 2017, an estimated $83K.
Prelude Capital Management first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 10 quarters.
Prelude Capital Management's Impax Laboratories, Inc. position peaked at $1.71M in Q3 2016.
172 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2017.

Based on Prelude Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.